Breaking News, Collaborations & Alliances

GSK Expands Cancer Research Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline has signed an agreement with the Ludwig Institute for Cancer Research (LICR) to license a substantial portfolio of tumor-specific antigens from LICR. The licensing agreement followed a long-standing collaboration between the groups on GSK’s investigational MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) in Non-Small Cell Lung Cancer (NSCLC). This novel cancer immunotherapy is based on MAGE-A3, a tumor-specific antigen previously in-licensed by GSK from LICR. Pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters